ENANTA PHARMACEUTICALS INC (ENTA) stock intrinsic value fair value estimate & owner earnings analysis

Enanta is a small drug royalty company. Its cash income comes almost entirely from a royalty AbbVie pays on worldwide sales of MAVYRET/MAVIRET, the hepatitis C treatment built around a compound Enanta discovered. Enanta does not sell anything itself; AbbVie manufactures and sells the drug in the United States and internationally, and Enanta collects a royalty on those net sales. Alongside this, Enanta funds its own early-stage research programs, most notably two respiratory-virus (RSV) drug candidates, zelicapavir and EDP-323, both of which have completed mid-stage (Phase 2) studies with encouraging results but have not been licensed to a partner or approved for sale. The royalty stream is fading. AbbVie's hepatitis C sales have declined for several years as competing treatments and a shrinking pool of untreated patients reduce the market, and Enanta's royalty revenue has fallen accordingly (from about $79 million in fiscal 2023 to about $65 million in fiscal 2025). A partial offset: in June 2025, the FDA approved MAVYRET for acute hepatitis C, which could broaden the treatable population under the existing royalty. The underlying U.S. patent on the drug's active ingredient is expected to expire in 2032, which is a reasonable point beyond which we do not assume any royalty continues, since nothing in the filings points to a further source of royalty income after that. In April 2023, Enanta sold a slice of this royalty stream to a pension-fund investor (OMERS) for $200 million upfront cash. Under that deal, 54.5% of the quarterly royalty must be forwarded to OMERS through mid-2032 (or until OMERS has received 1.42 times what it paid, whichever comes first). Enanta still books the full royalty as revenue for accounting purposes, but the cash that must be passed through to OMERS is not really available to Enanta's shareholders, so we have treated it as a real cost when estimating what the business generates for owners going forward, alongside removing one-time spending on a new office and lab building that Enanta completed in fiscal 2025. The central issue for value is that Enanta's research spending has, for several years, cost more than the royalty brings in. That gap has been funded from a large cash and investment cushion (roughly $200-plus million) and, most recently, from a new stock offering of roughly $70 million completed in the first quarter of fiscal 2026, which increased the share count by about a third. That decision - raising fresh equity specifically to keep funding the pipeline, rather than scaling back research or returning cash - indicates management intends to keep investing in the RSV programs for some time yet, even though neither candidate has a partner or approval. Because we can only assign value to things we can point to evidence for, and no RSV product has been licensed or approved, we have not put any value on the pipeline itself; it only enters this analysis as an ongoing cost until we see evidence otherwise. All three cases below assume the royalty keeps fading and ends by 2032, and that no value is assigned to the unproven pipeline. What separates them is how much longer the company keeps spending on research at something close to recent levels before cutting back to match the shrinking royalty, and how quickly the royalty itself fades. In the bear case, the royalty declines at close to its worst recent annual pace and research spending is trimmed only modestly rather than sharply. On that path, the cash cushion is largely used up within about two years, leaving little for shareholders once the company is forced into deeper cuts or additional dilutive financing - so this case is worth very little. In the base case, the royalty fades at roughly its average recent pace, and research spending is cut over the next couple of years broadly in line with the company's own statement (made after completing both RSV Phase 2 studies) that it expects research costs to decrease. Spending is gradually right-sized to track the shrinking royalty by around fiscal 2029 - consistent with the company's own estimate that its current resources fund it into that year. Under this path, most of today's cash cushion ends up funding the transition rather than being left over for shareholders, leaving only modest value per share. In the bull case, the royalty decline slows toward its best recent pace (helped by the broader acute hepatitis C approval), and research spending is cut sharply and quickly. The company reaches roughly breakeven operations by around fiscal 2031 without needing further stock sales, preserving most of today's cash for shareholders. We were not able to fully trace two small, non-cash reconciling items in the cash flow statement (an accounting adjustment tied to the OMERS royalty sale and a preferred-stock fair-value adjustment) to a plain-language explanation beyond what the filings state; both are small and do not affect the conclusions above. Given how much the outcome depends on how disciplined the company is about research spending relative to a shrinking royalty, and the real risk of a materially worse outcome if spending isn't cut quickly enough, the margin-of-safety price carries a large discount to the estimated value described above, and it applies only once there is clear evidence that spending cuts are actually happening.